Browse LILRB4

Summary
SymbolLILRB4
Nameleukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4
Aliases LIR-5; ILT3; HM18; LIR5; CD85k; ILT-3; CD85 antigen-like family member K; immunoglobulin-like transcript 3; ......
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Note=Ligand binding leads to internalization and translocation to an antigen-processing compartment.
Domain PF00047 Immunoglobulin domain
PF13895 Immunoglobulin domain
Function

Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. Involved in the down-regulation of the immune response and the development of tolerance, e.g. towards transplants. Interferes with TNFRSF5-signaling and NF-kappa-B up-regulation. Inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

> Gene Ontology
 
Biological Process GO:0002250 adaptive immune response
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0002762 negative regulation of myeloid leukocyte differentiation
GO:0030099 myeloid cell differentiation
GO:0030316 osteoclast differentiation
GO:0045637 regulation of myeloid cell differentiation
GO:0045638 negative regulation of myeloid cell differentiation
GO:0045670 regulation of osteoclast differentiation
GO:0045671 negative regulation of osteoclast differentiation
GO:0061614 pri-miRNA transcription from RNA polymerase II promoter
GO:1902105 regulation of leukocyte differentiation
GO:1902106 negative regulation of leukocyte differentiation
GO:1902893 regulation of pri-miRNA transcription from RNA polymerase II promoter
GO:1902894 negative regulation of pri-miRNA transcription from RNA polymerase II promoter
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
Molecular Function GO:0003823 antigen binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04380 Osteoclast differentiation
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Summary
SymbolLILRB4
Nameleukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4
Aliases LIR-5; ILT3; HM18; LIR5; CD85k; ILT-3; CD85 antigen-like family member K; immunoglobulin-like transcript 3; ......
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LILRB4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between LILRB4 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
17513794Colorectal Carcinoma; Pancreatic Carcinoma; MelanomaInhibit immunityFurthermore, we found that patients with melanoma, and carcinomas of the colon, rectum, and pancreas produce the soluble ILT3 protein, which induces the differentiation of CD8(+) T suppressor cells and impairs T cell responses in MLC. These responses are restored by anti-ILT3 mAb or by depletion of soluble ILT3 from the serum.
Summary
SymbolLILRB4
Nameleukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4
Aliases LIR-5; ILT3; HM18; LIR5; CD85k; ILT-3; CD85 antigen-like family member K; immunoglobulin-like transcript 3; ......
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LILRB4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLILRB4
Nameleukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4
Aliases LIR-5; ILT3; HM18; LIR5; CD85k; ILT-3; CD85 antigen-like family member K; immunoglobulin-like transcript 3; ......
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LILRB4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0860.839
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3320.826
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3880.723
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1740.768
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.870.592
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7110.74
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3780.519
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8260.566
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1860.911
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.5250.347
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.5610.548
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1280.566
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LILRB4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.35.98.40.576
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1032033.3-13.31
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.18.22.90.699
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.110.20.91
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.811.8-70.577
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)1311018.2-18.20.199
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.93.74.20.636
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLILRB4
Nameleukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4
Aliases LIR-5; ILT3; HM18; LIR5; CD85k; ILT-3; CD85 antigen-like family member K; immunoglobulin-like transcript 3; ......
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LILRB4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLILRB4
Nameleukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4
Aliases LIR-5; ILT3; HM18; LIR5; CD85k; ILT-3; CD85 antigen-like family member K; immunoglobulin-like transcript 3; ......
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LILRB4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LILRB4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLILRB4
Nameleukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4
Aliases LIR-5; ILT3; HM18; LIR5; CD85k; ILT-3; CD85 antigen-like family member K; immunoglobulin-like transcript 3; ......
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LILRB4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLILRB4
Nameleukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4
Aliases LIR-5; ILT3; HM18; LIR5; CD85k; ILT-3; CD85 antigen-like family member K; immunoglobulin-like transcript 3; ......
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LILRB4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLILRB4
Nameleukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4
Aliases LIR-5; ILT3; HM18; LIR5; CD85k; ILT-3; CD85 antigen-like family member K; immunoglobulin-like transcript 3; ......
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LILRB4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLILRB4
Nameleukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4
Aliases LIR-5; ILT3; HM18; LIR5; CD85k; ILT-3; CD85 antigen-like family member K; immunoglobulin-like transcript 3; ......
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LILRB4 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.